Respiratory Season 2024 - 2025: Immunizations for Pediatric and Adolescent Age Groups

Maine Immunization Program

September 2024

Respiratory Season 2024 - 2025

	What are the options?	Who is eligible?	How well do they work?	When should I get it?
INFLUENZA 	A shot that targets 3 strains of seasonal flu	6 months+	Reduces the risk of going to the doctor by 40-60%	October is ideal, as vaccine protection wanes over a season
COVID-19 	Updated vaccine formula targeting JN.1 or KP.2 – Omicron subvariants Options: Moderna and Pfizer (mRNA) or Novavax (protein)	6 months+	Last year, the fall vaccine provided 40-60% additional protection against severe disease	Protection against **severe disease**: Get now Protection against **infection**: Best to get it right before a wave, which can be challenging to time **Recently infected?** Wait at least 4-6 months
RSV MONOCLONAL ANTIBODY 	This is not a vaccine (doesn't teach the body to make antibodies) but rather a preventive medication (provides antibodies)	**All** infants <8 months if mother didn't get RSV vaccine during pregnancy. High-risk infants 8-19 months	Reduces risk of hospitalization by 80-96%	Protection lasts 4-6 months

Covid-19 Vaccine Clinical Considerations 2024 - 2025

Pediatric and Adolescent Age Groups

People who are not moderately or severely immunocompromised

Initial vaccination

- Ages 6 months–4 years
  - 2 doses of 2024–2025 Moderna or 3 doses of 2024–2025 Pfizer-BioNTech
- Ages 5 years and older
  - 1 dose of 2024–2025 Moderna or 1 dose of 2024–2025 Pfizer-BioNTech

Received previous doses of a COVID-19 vaccine

- Ages 6 months–4 years
  - 1 or 2 doses of 2024–2025 mRNA vaccine from the same manufacturer as administered for initial vaccination, depending on the vaccine and the number of prior doses
- Ages 5 years and older
  - 1 dose of 2024–2025 Moderna or 1 dose of 2024–2025 Pfizer-BioNTech

Additional dose: An additional dose of 2024–2025 COVID-19 vaccine for people ages 65 years and older who are not moderately or severely immunocompromised is NOT currently recommended.

https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

Covid-19 Vaccine NEW Presentations 2024 - 2025

Pediatric and Adolescent Age Groups

Trade Name/ NDC#	MIP ordering recommendations for specific patient population	Presentations
Moderna/80777-0291-80	6m - 11 years	Prefilled syringe
Moderna/80777-0110-93*	12 years and older	
Novavax /80631-0107-10*	12 years and older	Prefilled syringe
Pfizer/59267-4426-02	6m – 4 years	Multi-dose vial
Pfizer/59267-4438-02	5 – 11 years	Single dose vial
Pfizer/00069-2432-10*	12 years and older	Prefilled syringe

Covid-19 Vaccine Storage & Handling- Moderna

Moderna/ Spikevax

The following requirements apply to both Moderna COVID-19 Vaccine 2024-2025 Formula and SPIKEVAX®:

•Store frozen between -50ºC to -15ºC (-58ºF to 5ºF)

•After thawing, products may be stored refrigerated between 2ºC to 8ºC (36ºF to 46ºF) for up to 60 days or up to the expiration date printed on the carton, **whichever comes first**

•After thawing, products may be stored between 8ºC to 25ºC (46ºF to 77ºF) for up to 12 hours

•Do not refreeze once thawed

Covid-19 Vaccine Storage & Handling- Pfizer 6mo through 11yr

6mo-5yr & 6yr-11yr old:

Unopened, frozen vaccine

- Once received, frozen vials may be stored in an ultra-low temperature freezer at -90°C to -60°C until the expiration date printed on the vials and cartons. Do not store vials at -25°C to -15°C.
- Once vials are thawed, they should not be refrozen.

Unopened, refrigerated vaccine

- Once received, frozen vials may be immediately transferred to the refrigerator [2°C to 8°C], thawed and stored for up to 10 weeks, not to exceed the expiration date printed on the vial and cartons.
- If vials and cartons are received at 2°C to 8°C, they should be stored at 2°C to 8°C.
- Check that the carton has been updated to reflect the 10-week refrigerated expiry date, not to exceed the expiration date printed on the vial and cartons.

Opened, refrigerated vaccine

- If not previously thawed at 2°C to 8°C, allow multi-dose vials or single dose vials to thaw at room temperature [up to 25°C (77°F)] for 30 minutes. Multi-dose or single dose vials may be stored at room temperature [8°C to 25°C] for a total of 12 hours prior to the first puncture.
- After dilution, multiple dose vials should be held between 2°C to 25°C. Multi-dose vials should be discarded 12 hours after dilution.

Covid-19 Vaccine Storage & Handling- Pfizer 12 Years and Older

Unopened, refrigerated vaccine (the 12 yr and older formulation can not be frozen)

- The vaccine may be stored at 2°C to 8°C until the expiration date printed on the carton and syringe labels (not to exceed 8 months). **DO NOT FREEZE**.

Opened, refrigerated vaccine

- After removing the tip cap and attaching an appropriate needle, the glass prefilled syringe should be used immediately. If it cannot be used immediately, it must be used within 4 hours. **DO NOT FREEZE**.

Opened, room temperature vaccine

- After removing the tip cap and attaching an appropriate needle, the glass prefilled syringe should be used immediately. If it cannot be used immediately, it must be used within 4 hours. **DO NOT FREEZE**.

Diluent :

- Reconstitution is required only for the Pfizer-BioNTech COVID-19 Vaccine for individuals 6 months through 4 years of age in multi-dose vials.

Pediatric and Adolescent Influenza Recommendations 2024 - 2025

The CDC recommends that every person aged 6months and older get the flu vaccine by the end of October. It does take up to two weeks after vaccination to be protected from the flu.

All flu vaccine for the 2024-2025 season are Trivalent vs. the previous quadrivalent formulation. This change is due to one of last years strains no longer circulating.

When should vaccination start?

- If only 1 dose is needed for the season, vaccination should ideally be done during September or October. Though it is recommended vaccination continue throughout the season if influenza is circulating.
- Children 6 months through 8 years who require 2 doses should receive the first dose as soon as vaccine is available.

Flu Vaccines Offered by The Maine Immunization Program 2024 - 2025

Trade Name/ NDC#	MIP ordering recommendations for specific patient population	Presentations
FluMist/66019-0311-10	Children 2 – 18 years	0.2mL single dose sprayer, 10 pack
FluLaval/19515-0810-52	Children 6 months – 18 years	0.50mL prefilled syringe, 10 pack
Fluzone/49281-0424-50*	Children 6 months – 18 years Adults 19 years and older (under and uninsured)	0.5mL prefilled syringe, 10 pack
Flucelvax/70461-0654-03	Children 6 months – 18 years	0.5mL prefilled syringe, 10 pack

All presentations of these vaccines must be refrigerated between 36°F and 46°F

FluLaval, Flucelvax and FluMist need to be protected from light

FluMist – Protection Without The Injection

Flu protection without the injection!

- FluMist helps prevent flu in people aged 2-49. It's a nasal spray flu vaccine that starts working in the nose.

- FluMist continues to trigger your immune system to help build antibodies against influenza in 3 ways :

FluMist Dosing:

- 1 spray in each nostril = a single dose
- People 9 years of age and older need 1 dose of FluMist each year
- Children 2 through 8 years old may need 2 doses of FluMist,depending on their history of previous influenza vaccination. Your healthcare provider will decide if your child needs to come back for a second dose

Vaccine Coadministration



Studies conducted throughout the COVID-19 pandemic indicate that it is safe to get both a flu vaccine and a COVID-19 vaccine at the same visit

Nirsevimab 2024 - 2025

Nirsevimab is recommended for infants younger than 8 months of age who were born during or are entering their first RSV season if:

- The mother did not receive an RSV vaccine during pregnancy.
- The mother's RSV vaccination status is unknown.
- The infant was born within 14 days of maternal RSV vaccination.

Most infants whose mothers got the RSV vaccine don't need to get nirsevimab too.

Some infants and young children 8 through 19 months of age who are at increased risk for severe RSV disease should receive nirsevimab shortly before the start of their second RSV season:

- Children who were born prematurely and have chronic lung disease.
- Children with severe immunocompromise.
- Children with cystic fibrosis who have severe disease.
- American Indian and Alaska Native children.

Children who should get nirsevimab but have not yet done so may get nirsevimab at any time during RSV season.

RSV is the LEADING CAUSE of infant hospitalization in the U.S.

Nirsevimab Season 2024 - 2025

CDC recommends RSV immunizations during specific months to maximize protection during RSV season. RSV typically peaks between December and February. It is important that babies have protection before RSV season starts.



Nirsevimab Presentations

Dosing and Administration

The recommended dosage of Beyfortus in neonates and infants born during or entering their first RSV season is based on body weight and is administered as one single intramuscular (IM) injection.[5]

Recommended Dosage of Beyfortus in Neonates and Infants Born During or Entering Their First RSV Season[5]

Body Weight at Time of Dosing	Recommended Dosage
Less than 5 kg	50 mg by IM injection
5 kg and greater	100 mg by IM injection

50 mg by IM injection

100 mg by IM injection

Nirsevimab should be stored in the fridge between 36°F and 46°F . Once removed from the fridge, Nirsevimab must be used within 8 hours or discarded.

Resources

- CDC Recommends Updated COVID-19 Vaccine for Fall/Winter Virus Season | CDC Online Newsroom | CDC
- Prevent Seasonal Flu | CDC
- Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC
- FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants | FDA
- Who Needs a Flu Vaccine | CDC
- Immunization | Maine CDC | DHHS
- https://www.cdc.gov/vaccines/php/info-by-product/pfizer-covid-19-summary.html
- https://www.cdc.gov/vaccines/php/info-by-product/moderna-covid-19-summary.html

Questions?

Moria Pratt
Public Health Educator
Moria.Pratt@Maine.Gov
207-287-4466